The generating function that has all coefficients 1 is given by

  
    
      
        
          
            1
            
              1
              −
              x
            
          
        
        =
        1
        +
        x
        +
        
          x
          
            2
          
        
        +
        
          x
          
            3
          
        
        +
        …
      
    
    {\displaystyle {\frac {1}{1-x}}=1+x+x^{2}+x^{3}+\ldots }
  
This power series converges and has finite value if and only if 
  
    
      
        
          |
        
        x
        
          |
        
        <
        1
      
    
    {\displaystyle |x|<1}
  .
Potassium iodate (KIO3) is used to iodize some salts so that the iodine is not lost by oxidation. Dextrose or sodium thiosulfate are often added to iodized table salt to stabilize potassium iodide thus reducing loss of the volatile chemical. Thyroid protection
Thyroid iodine uptake blockade with potassium iodide is used in nuclear medicine scintigraphy and therapy with some radioiodinated compounds that are not targeted to the thyroid, such as iobenguane (MIBG), which is used to image or treat neural tissue tumors, or iodinated fibrinogen, which is used in fibrinogen scans to investigate clotting. These compounds contain iodine, but not in the iodide form. However, since they may be ultimately metabolized or break down to radioactive iodide, it is common to administer non-radioactive potassium iodide to ensure that iodide from these radiopharmaceuticals is not sequestered by the normal affinity of the thyroid for iodide. U.S. Food and Drug Administration-approved dosing of potassium iodide for this purpose with iobenguane, is as follows (per 24 hours): infants less than 1 month old, 16 mg; children 1 month to 3 years, 32 mg; children 3 years to 18 years, 65 mg; adults 130 mg. However, some sources recommend alternative dosing regimens.Not all sources are in agreement on the necessary duration of thyroid blockade, although agreement appears to have been reached about the necessity of blockade for both scintigraphic and therapeutic applications of iobenguane.